Gyre Therapeutics' Hydronidone Cleared for Conditional Approval Pathway, Priority Review in China

summarizeSummary

Gyre Therapeutics announced that China's CDE agreed to a conditional approval pathway and priority review eligibility for its anti-fibrotic therapy, Hydronidone, based on positive Phase 3 data, with an NDA submission planned for H1 2026.

check_boxKey Events

• CDE Alignment on Conditional Approval

  China's Center for Drug Evaluation (CDE) agreed that existing Phase 3 clinical data for Hydronidone generally support a conditional approval New Drug Application (NDA) for CHB-associated liver fibrosis.

• Priority Review Eligibility Confirmed

  The CDE indicated that Hydronidone meets the criteria for inclusion in China's Priority Review and Approval Program for Innovative Drugs, subject to formal filing and review.

• NDA Submission Planned for H1 2026

  Gyre Pharmaceuticals plans to submit the conditional approval NDA for Hydronidone in the first half of 2026.

• Confirmatory Clinical Trial Planned

  An additional confirmatory Phase 3c clinical trial will be conducted to support potential conversion from conditional to regular approval.

auto_awesomeAnalysis

This 8-K filing signals a significant regulatory advancement for Gyre Therapeutics' lead anti-fibrotic drug, Hydronidone, in the substantial Chinese market. The consensus reached with China's CDE for a conditional approval pathway and eligibility for priority review substantially de-risks the drug's path to commercialization. This development, building on previously reported positive Phase 3 results and Breakthrough Therapy Designation, positions Hydronidone to address a large unmet medical need in chronic hepatitis B-associated liver fibrosis. Investors should monitor the upcoming NDA submission in the first half of 2026 and the progress of the confirmatory clinical trial for full approval.